Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27576132
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Mechanisms of heparanase inhibitors in cancer therapy
#MMPMID27576132
Heyman B
; Yang Y
Exp Hematol
2016[Nov]; 44
(11
): 1002-1012
PMID27576132
show ga
Heparanase is an endo-?-D-glucuronidase capable of cleaving heparan sulfate side
chains contributing to breakdown of the extracellular matrix. Increased
expression of heparanase has been observed in numerous malignancies and is
associated with a poor prognosis. It has generated significant interest as a
potential antineoplastic target because of the multiple roles it plays in tumor
growth and metastasis. The protumorigenic effects of heparanase are enhanced by
the release of heparan sulfate side chains, with subsequent increase in bioactive
fragments and cytokine levels that promote tumor invasion, angiogenesis, and
metastasis. Preclinical experiments have found heparanase inhibitors to
substantially reduce tumor growth and metastasis, leading to clinical trials with
heparan sulfate mimetics. In this review, we examine the role of heparanase in
tumor biology and its interaction with heparan surface proteoglycans,
specifically syndecan-1, as well as the mechanism of action for heparanase
inhibitors developed as antineoplastic therapeutics.
|Animals
[MESH]
|Antineoplastic Agents/*pharmacology/*therapeutic use
[MESH]
|Cancer Vaccines
[MESH]
|Clinical Trials as Topic
[MESH]
|Drug Evaluation, Preclinical
[MESH]
|Enzyme Inhibitors/*pharmacology/*therapeutic use
[MESH]
free
free
free
